Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2”

166 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 166 results

Large-scale testing (Phase 3)Study completedNCT02184195
What this trial is testing

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Who this might be right for
Germline BRCA1/2 Mutations andMetastatic Adenocarcinoma of the Pancreas
AstraZeneca 154
Testing effectiveness (Phase 2)Study completedNCT02797977
What this trial is testing

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Who this might be right for
Advanced Solid Tumors
Sierra Oncology LLC - a GSK company 153
Early research (Phase 1)Looking for participantsNCT06488378
What this trial is testing

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast Cancer+2 more
Dana-Farber Cancer Institute 20
Early research (Phase 1)Looking for participantsNCT06177171
What this trial is testing

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Who this might be right for
BRCA1 MutationBRCA2 MutationBRCA Mutation+3 more
Pamela Munster 18
Not applicableStudy completedNCT03159572
What this trial is testing

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 996
Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Not applicableStudy completedNCT05750719
What this trial is testing

BRCA and NACT in TNBC Patients

Who this might be right for
Triple-Negative Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 136
Testing effectiveness (Phase 2)Study completedNCT02797964
What this trial is testing

A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

Who this might be right for
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
Sierra Oncology LLC - a GSK company 107
Testing effectiveness (Phase 2)Ended earlyNCT02326844
What this trial is testing

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Who this might be right for
Ovarian Cancer
National Cancer Institute (NCI) 3
Early research (Phase 1)Study completedNCT03509636
What this trial is testing

Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd. 113
Not applicableStudy completedNCT03684733
What this trial is testing

Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer

Who this might be right for
BRCA1 MutationBRCA2 MutationMammography+1 more
Royal Marsden NHS Foundation Trust 28
Not applicableUnknownNCT04368442
What this trial is testing

Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation

Who this might be right for
Breast Cancer Metastatic
Samsung Medical Center 583
Not applicableActive Not RecruitingNCT02653105
What this trial is testing

Women at Risk of Breast Cancer and OLFM4

Who this might be right for
Hereditary Breast and Ovarian Cancer Syndrome
Institut Cancerologie de l'Ouest 150
Not applicableActive Not RecruitingNCT02206360
What this trial is testing

Pancreatic Cancer Early Detection Program

Who this might be right for
Pancreatic CancerPancreas CancerPancreatic Adenocarcinoma+8 more
White Plains Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06533384
What this trial is testing

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Who this might be right for
Triple-negative Breast Cancer
Guangdong Provincial People's Hospital 310
Early research (Phase 1)Study completedNCT01445418
What this trial is testing

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Who this might be right for
Breast CancerOvarian Cancer
National Cancer Institute (NCI) 103
Early research (Phase 1)Study completedNCT01339650
What this trial is testing

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian TubePrimary Peritoneal CancerSolid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian
AbbVie (prior sponsor, Abbott) 93
Not applicableLooking for participantsNCT02516540
What this trial is testing

Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers

Who this might be right for
Hereditary Breast and Ovarian Cancer
Technical University of Munich 600
Testing effectiveness (Phase 2)WithdrawnNCT05482074
What this trial is testing

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Who this might be right for
Recurrent Metastatic MelanomaCutaneous MelanomaMucosal Melanoma+1 more
Dana-Farber Cancer Institute
Not applicableLooking for participantsNCT06726642
What this trial is testing

CfDNA in Hereditary And High-risk Malignancies 2

Who this might be right for
Hereditary Cancer Syndrome
University Health Network, Toronto 1,000
Load More Results